The content on this site is intended for healthcare professionals only
Dr Kurt Miller from Berlin, Germany, argues against chemotherapy remaining as the standard treatment for symptomatic mCRPC in the era of novel agents.
He shows the strong evidence supporting agents in the pre-chemotherapy space, such as abiraterone and enzalutamide.
He also shows the evidence supporting sipuleucel-T and alpharadin. Dr Miller notes that chemotherapy will still have a role in mCRPC, but probably second-, third- or fourth-line.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
